Immix Biopharma Gives Update on Clinical Data for Rare Disease Drug Candidate; Shares Lower-February 2024-www.financetom.com

Immix Biopharma Gives Update on Clinical Data for Rare Disease Drug Candidate; Shares Lower

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Immix Biopharma Gives Update on Clinical Data for Rare Disease Drug Candidate; Shares Lower

Dec 10, 2024 8:31 AM

11:09 AM EST, 12/10/2024 (MT Newswires) -- Immix Biopharma ( IMMX ) said Tuesday that updated data for its drug NXC-201 showed a 94% overall response rate in patients with AL amyloidosis.

The drug had a complete response rate of 75% in the phase 1b/2 Nexicart-1 study, according to the company.

One patient maintained a complete response for 31.5 months, with ongoing remission as of Dec. 9, Immix added.

Shares of Immix were down 7.4% in recent trading.

Price: 2.25, Change: -0.29, Percent Change: -11.42

Previous page： 3M CFO Patolawala to leave by end of July Next page： Honeywell to buy Air Products' LNG business for $1.8 bln, WSJ reports

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.